Uncertainties cloud Pharmaniaga


The optimism on the new vaccine division, which hinges solely on the Sinovac vaccine, looks uncertain and makes earnings forecasts difficult.

PETALING JAYA: Earnings visibility appears murky beyond 2021 for Pharmaniaga Bhd as it has yet to get an extension for its medical supply contract from the government which expires by year-end.

Pharmaniaga is the largest listed pharmaceutical company in the country by revenue with the government’s drug and medical supply concession in-hand.

Save 30% OFF The Star Digital Access

Monthly Plan

RM 13.90/month

RM 9.73/month

Billed as RM 9.73 for the 1st month, RM 13.90 thereafter.

Best Value

Annual Plan

RM 12.33/month

RM 8.63/month

Billed as RM 103.60 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

HSS Engineers' associate secures RM22mil EPCC job for data centre in Perak
Oil edges up after Trump backs off tariff threat on Greenland
Guan Huat Seng opens slightly lower at 24 sen in ACE Market debut
Australian dollar scales 15-month high on strong jobs data
Gold dips, stocks lift as Trump walks back Greenland threats
Ringgit opens firmer on OPR hold expectations
Bursa Malaysia tracks global rebound as Trump walks back tariffs threat
Trading ideas: Sunway, IJM, Binastra, Capital A, Elridge, Oxford Innotech, Steel Hawk, Carimin, SMRT, Reneuco, Suria, KIP REIT, Pantech
Wall Street jumps on Greenland framework deal
Wasco to gain from transition to renewables

Others Also Read